Phoenix Life
Sciences Receives Import Certificate for Cannabis Diabetes Drug
from the Republic of Vanuatu
DENVER, CO --
November 14,
2018 -- InvestorsHub NewsWire --
Phoenix Life Sciences International Limited (OTCMarkets:
PLSI)
("Phoenix Life"), an international
adaptive healthcare
solutions company, today announced that it has received an import
certificate
from the Republic of Vanuatu's Minister of Health
to bring
its cannabis
diabetes drug Phoenix Metabolic
into the country
for clinical trials.
"With this
certificate, we look forward to playing
a pivotal role in
decreasing the size of the global diabetes epidemic," said Phoenix Life Sciences
International CEO Martin Tindall. "The Republic of Vanuatu just
took its first steps to legalize medical cannabis throughout the
nation, and
we are
thrilled to be at the forefront of the industry during this
historic
time."
Phoenix Life can
now import
its cannabis-based diabetes drug into Vanuatu and the company hopes to soon announce the launch of clinical trials
for its
first 1,000 patients.
In the Republic of
Vanuatu, a South Pacific island nation comprised of roughly 80
islands, about 13 percent of the population has diabetes. That translates to
about 35,000 of the 265,000 residents, making diabetes the largest
cost to the nation's healthcare system. Phoenix
Metabolic has the potential to
significantly decrease Vanuatu's yearly cost of diabetes treatments
while providing a natural, safer alternative to traditional
pharmaceutical medications.
"This
certificate
is the first step
in transforming the health of an entire island nation based on a
comprehensive, scientific approach to modern illness and disease
prevention," said Dr. Philip Blair, Diabetes Director of the
Phoenix Life Sciences International Medical Advisory
Council.
Phoenix Life
plans to
utilize a
vertically-integrated operation to produce its medical cannabis
pharmaceutical products and ensure maximum efficacy.
The company aims to
partner with the single-payer healthcare systems of both
established and emerging economies to conduct medical studies on
cannabis for diabetes and establish programs for diabetes patients
to receive the company's botanical products.
For more
information on Phoenix Life, please visit
https://plsi.co/.
###
About Phoenix
Life Sciences International Limited
Phoenix Life
Sciences International Limited (OTCMarkets:
PLSI) is
an adaptive healthcare solutions company. Our business is to
advance research and integrate programs and manufacturing of
products that target and treat diabetes, pain, cancer, and address
psychological, gastrointestinal, autoimmune, neurological and sleep
disorders. We strive to create partnerships and integrate these
programs for human health into communities worldwide as part of our
Global Health Initiative.
FORWARD-LOOKING
STATEMENTS
Information
contained in this press release regarding Phoenix Life Sciences
International, Limited and its subsidiaries, (the "Companies") may
constitute forward-looking statements or statements which may be
deemed or construed to be forward-looking statements. The words
"plan", "forecast", "anticipates", "estimate", "project", "intend",
"expect", "should", "believe," and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to, known and unknown risks,
uncertainties and other factors which could cause the Company's
actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in the Company's filings with the
U.S. Securities and Exchange Commission. All forward-looking
statements attributable to the Companies herein are expressly
qualified in their entirety by the above-mentioned cautionary
statement. The Companies disclaim any obligation to update
forward-looking statements contained in this press release, except
as may be required by law.
FOOD AND DRUG
ADMINISTRATION (FDA) DISCLOSURE
These statements
have not been evaluated by the FDA and therefore the products sold
by Phoenix Life Sciences International are not available on
U.S. markets.
LEGAL
DISCLOSURE
Phoenix Life
Sciences International does not sell or distribute any products in
the United States that are in violation of the United States
Controlled Substances Act (US.CSA). This company does not grow,
sell, and distribute cannabis-based products in the United States
and is solely involved with the legal distribution of medical
cannabis-based products within certain international markets
outside of the United States.
Investor
Contact:
Phone:
1.888.717.5655 or international +1.720.699.7222
E-mail:
investor.relations@phoenixlife.co
Media
Contact:
Kathryn
Reinhardt
CMW
Media
Kathryn@cmwmedia.com
619-972-3089